<div id="readability-page-1"><p>Galectin Therapeutics Inc. (NASDAQ:GALT - Get Free Report) CEO Joel Lewis sold 27,731 shares of the business's stock in a transaction on Monday, January 5th. The stock was sold at an average price of $3.91, for a total value of $108,428.21. Following the completion of the transaction, the chief executive officer directly owned 870,290 shares of the company's stock, valued at approximately $3,402,833.90. The trade was a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website.</p><div><p><span></span><span>Get <strong>Galectin Therapeutics</strong> alerts:</span></p></div><p>Joel Lewis also recently made the following trade(s): </p><ul><li>On Tuesday, January 6th, Joel Lewis sold 37,698 shares of Galectin Therapeutics stock. The shares were sold at an average price of $3.58, for a total value of $134,958.84. </li><li>On Friday, January 2nd, Joel Lewis sold 18,571 shares of Galectin Therapeutics stock. The shares were sold at an average price of $4.20, for a total value of $77,998.20. </li><li>On Wednesday, December 17th, Joel Lewis sold 7,829 shares of Galectin Therapeutics stock. The shares were sold at an average price of $7.06, for a total transaction of $55,272.74. </li><li>On Wednesday, November 5th, Joel Lewis sold 200 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.00, for a total transaction of $1,200.00. </li><li>On Tuesday, November 4th, Joel Lewis sold 14,420 shares of Galectin Therapeutics stock. The shares were sold at an average price of $6.07, for a total transaction of $87,529.40. </li><li>On Monday, November 3rd, Joel Lewis sold 1,300 shares of Galectin Therapeutics stock. The stock was sold at an average price of $6.01, for a total transaction of $7,813.00. </li></ul><h2>Galectin Therapeutics Stock Down 11.1%</h2><p>Shares of Galectin Therapeutics stock traded down $0.43 during trading on Tuesday, reaching $3.45. The company's stock had a trading volume of 905,529 shares, compared to its average volume of 684,117. The company has a 50-day simple moving average of $5.34 and a two-hundred day simple moving average of $4.39. Galectin Therapeutics Inc. has a 1-year low of $1.07 and a 1-year high of $7.13. The company has a market cap of $222.42 million, a price-to-earnings ratio of -5.85 and a beta of 1.03. </p><p>Galectin Therapeutics (NASDAQ:GALT - Get Free Report) last issued its quarterly earnings results on Friday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.11) by ($0.02).  As a group, analysts anticipate that  Galectin Therapeutics Inc. will post -0.73 earnings per share for the current year. </p><h2>Hedge Funds Weigh In On Galectin Therapeutics</h2><p>A number of hedge funds have recently bought and sold shares of the business. Vanguard Group Inc. grew its holdings in  Galectin Therapeutics by 2.9% in the third quarter. Vanguard Group Inc. now owns 2,247,967 shares of the company's stock valued at $9,520,000 after purchasing an additional 63,419 shares during the period.  Osaic Holdings Inc. grew its stake in  Galectin Therapeutics by 3.4% in the 2nd quarter. Osaic Holdings Inc. now owns 1,265,384 shares of the company's stock valued at $2,670,000 after acquiring an additional 41,968 shares during the period.  Jane Street Group LLC purchased a new stake in  Galectin Therapeutics in the 2nd quarter worth $1,580,000.  Wealthspire Advisors LLC raised its position in  Galectin Therapeutics by 20.4% during the second quarter. Wealthspire Advisors LLC now owns 479,518 shares of the company's stock worth $1,012,000 after acquiring an additional 81,144 shares during the period.  Finally, Geneos Wealth Management Inc. lifted its holdings in  Galectin Therapeutics by 8.8% during the first quarter. Geneos Wealth Management Inc. now owns 423,235 shares of the company's stock valued at $516,000 after purchasing an additional 34,300 shares in the last quarter. Hedge funds and other institutional investors own  11.68% of the company's stock. </p><h2>Analyst Ratings Changes</h2><p>Several brokerages have commented on GALT. Weiss Ratings  restated a &#34;sell (d-)&#34; rating on shares of Galectin Therapeutics in a research note on Wednesday, October 8th. HC Wainwright raised their price objective on shares of Galectin Therapeutics from $6.00 to $11.00 and gave the stock a &#34;buy&#34; rating in a research note on Wednesday, December 17th. One investment analyst  has rated the stock with a Buy rating and one  has given a Sell rating to the stock. According to MarketBeat.com, the stock  has a consensus rating of &#34;Hold&#34; and an average price target of $11.00.</p><p><b>Check Out Our Latest Analysis on Galectin Therapeutics</b></p><h2>Key Stores Impacting Galectin Therapeutics</h2><p>Here are the key news stories impacting Galectin Therapeutics this week:</p><ul>   <li><span>Negative Sentiment: </span>CEO Joel Lewis sold multiple blocks of stock (Jan. 2, Jan. 5 and Jan. 6), totaling 83, (serial sales of 18,571; 27,731; 37,698 shares) at average prices around $4.20–$3.58, reducing his stake by ~4% overall — signaling significant insider liquidity. <i></i><span>CEO Joel Lewis Form 4</span></li>    <li><span>Negative Sentiment: </span>CFO Jack W. Callicutt also executed staged sales (Jan. 2, Jan. 5 and Jan. 6), selling roughly 59, (13,914; 25,732; 20,354 shares) at avg. prices ~$4.20–$3.67, cutting his direct holdings by a large percentage — another material insider reduction. <i></i><span>CFO Jack W. Callicutt Form 4</span></li>    <li><span>Negative Sentiment: </span>Director/insider Khurram Jamil sold multiple tranches (Jan. 2, Jan. 5 and Jan. 6) totaling ~60,000+ shares across those dates at avg. prices from $4.20 to $3.65, substantially reducing his position — further insider selling pressure. <i></i><span>Khurram Jamil Form 4</span></li>    <li><span>Negative Sentiment: </span>Pomerantz LLP announced an investor investigation into Galectin on Jan. 6, which can increase legal risk and heighten short‑term selling pressure. <i></i><span>Pomerantz Investor Alert</span></li> </ul><h2>About Galectin Therapeutics</h2> (Get Free Report)<p>Galectin Therapeutics, Inc is a clinical-stage biotechnology company focused on the development of novel therapies that target galectin proteins, which are implicated in fibrotic, inflammatory and malignant diseases. The company's lead product candidate, belapectin (formerly GR-MD-02), is a galectin-3 inhibitor being evaluated in Phase 2 clinical trials for nonalcoholic steatohepatitis (NASH) with cirrhosis. In addition to its core pipeline in fibrotic liver disease, Galectin Therapeutics continues to explore the potential of its galectin inhibitors in oncology and other indications driven by abnormal tissue remodeling.  </p><p>Founded in 2000, the company is headquartered in Norcross, Georgia, where it oversees discovery research, preclinical studies and clinical trial coordination.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Galectin Therapeutics</li><li>A month before the crash</li><li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li><li>How a Family Trust May Be Able To Help Preserve Your Wealth</li><li>S&amp;P 8000</li><li>BNZI: BNZI Surges Ahead as AI Marketing Fuels Record Revenue</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0FMVA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/InsiderTradesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9R0FMVA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Galectin Therapeutics Right Now?</h2><p>Before you consider Galectin Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Galectin Therapeutics wasn't on the list.</p><p>While Galectin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GALT

<p>Galectin Therapeutics CEO Joel Lewis sold 27,731 shares of the company's stock at an average price of $3.91, totaling $108,428.21. Post-sale, he owns 870,290 shares, a 3.09% decrease in ownership. The stock has seen a decline of 11.1%, trading at $3.45. Galectin's market cap is $222.42 million, with a P/E ratio of -5.85. Analysts expect a loss of -0.73 EPS for the year. Hedge funds hold 11.68% of the stock, with recent activity from Vanguard and Osaic Holdings. Brokerages have mixed ratings on GALT, with HC Wainwright setting a price target of $11.00.</p>

Joel Lewis Sells 27,731 Shares of Galectin Therapeutics (NASDAQ:GALT) Stock